Modifying dolutegravir to PrEPare for long life

Anti-retroviral therapy with drugs like dolutegravir is a powerful tool in both the treatment and prevention of HIV, but is limited by strict adherence to a daily therapeutic regimen. In a recent study, Deodhar, Sillman, and colleagues developed a dolutegravir prodrug that offers long-lasting protec...

Descripción completa

Detalles Bibliográficos
Autor principal: Mandarino, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640719/
https://www.ncbi.nlm.nih.gov/pubmed/36344610
http://dx.doi.org/10.1038/s42003-022-04114-0
_version_ 1784825922016247808
author Mandarino, Angelo
author_facet Mandarino, Angelo
author_sort Mandarino, Angelo
collection PubMed
description Anti-retroviral therapy with drugs like dolutegravir is a powerful tool in both the treatment and prevention of HIV, but is limited by strict adherence to a daily therapeutic regimen. In a recent study, Deodhar, Sillman, and colleagues developed a dolutegravir prodrug that offers long-lasting protection against HIV infection, with the potential to dramatically improve anti-retroviral therapy efficacy.
format Online
Article
Text
id pubmed-9640719
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96407192022-11-15 Modifying dolutegravir to PrEPare for long life Mandarino, Angelo Commun Biol Research Highlight Anti-retroviral therapy with drugs like dolutegravir is a powerful tool in both the treatment and prevention of HIV, but is limited by strict adherence to a daily therapeutic regimen. In a recent study, Deodhar, Sillman, and colleagues developed a dolutegravir prodrug that offers long-lasting protection against HIV infection, with the potential to dramatically improve anti-retroviral therapy efficacy. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640719/ /pubmed/36344610 http://dx.doi.org/10.1038/s42003-022-04114-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Mandarino, Angelo
Modifying dolutegravir to PrEPare for long life
title Modifying dolutegravir to PrEPare for long life
title_full Modifying dolutegravir to PrEPare for long life
title_fullStr Modifying dolutegravir to PrEPare for long life
title_full_unstemmed Modifying dolutegravir to PrEPare for long life
title_short Modifying dolutegravir to PrEPare for long life
title_sort modifying dolutegravir to prepare for long life
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640719/
https://www.ncbi.nlm.nih.gov/pubmed/36344610
http://dx.doi.org/10.1038/s42003-022-04114-0
work_keys_str_mv AT mandarinoangelo modifyingdolutegravirtoprepareforlonglife

Ejemplares similares